OPDP Untitled and Warning Letters: What Media Teams Can Learn
What OPDP untitled letters and warning letters are, the themes that recur, how media format and placement contribute, and how to read the letters on FDA's site.
The short answer
OPDP untitled and warning letters are FDA's public notices that a specific promotional piece was false or misleading. For media teams, the useful lesson is that many cited problems are format and placement problems: risk information that is too small, too fast, at the end of a skippable video, or missing from a social post, and claims that outrun the label. Reading the letters on FDA's site is the cheapest compliance training available.
Most media people never read an OPDP letter. That is a missed opportunity. The letters describe, in plain enough language, exactly which part of an ad FDA found misleading, and many of those parts are things a planner or ad ops lead controls. This article explains what the letters are, the themes that recur, and how to turn them into checks on your own plans. It is not legal advice and does not summarize any specific letter; read the originals on FDA's site.
What OPDP untitled and warning letters are
The Office of Prescription Drug Promotion sits within FDA's Center for Drug Evaluation and Research. Among other duties, it reviews promotional materials, handles complaints, and issues compliance letters when it believes promotion is false or misleading under the FD&C Act and 21 CFR 202.1.
| Untitled letter | Warning letter | |
|---|---|---|
| Seriousness | Violations FDA considers less serious | Violations FDA considers significant |
| Typical request | Stop using the cited material and similar materials | Stop, plus corrective action, often including corrective messaging to the audience that saw the ad |
| Response | Written response describing the plan | Written response; FDA may take further action if unresolved |
| Where posted | OPDP Untitled Letters page | FDA warning letter database |
Two practical notes. FDA generally does not pre-approve ads, so letters arrive after a piece has been in market. And because the letter goes to the manufacturer, agencies sometimes never see it unless the brand team shares it.
Why enforcement volume matters right now
For several years the number of OPDP letters was very low; public reports put warning letters at one in 2023 and none in 2024. That changed in September 2025, when HHS and FDA announced a broad DTC enforcement effort, including a large batch of letters to drug companies and telehealth firms, and signaled more monitoring of social media. Additional waves were reported into 2026. Treat those numbers as reported figures and check FDA's pages for the current picture.
The practical effect is that a piece that might have drawn no attention a few years ago is now more likely to be seen and cited. Legacy creative that has been running unchanged for a long time deserves a second look.
Common themes in OPDP letters
Without pointing to any particular letter, the recurring categories are well established and track the regulation:
- Omission or minimization of risk. Risk information missing, presented with far less prominence than benefits, or undercut by distracting visuals, music, or fast pacing.
- Overstatement of efficacy. Claims that go beyond what the clinical data or label support, including implied claims through imagery (for example, a patient shown doing things the trial did not measure).
- Unsubstantiated superiority or comparative claims. Suggesting a drug is better or faster than alternatives without adequate head-to-head evidence.
- Broadening the indication. Wording or visuals that suggest use in a wider population than approved.
- Misleading net impression. Each sentence may be technically accurate, but the ad as a whole leaves a misleading takeaway. Recent commentary on 2025 and 2026 letters emphasizes this theme, especially for quality-of-life and emotional benefit messaging.
- Sponsored social and influencer content. Paid posts, interviews, or partner content treated as promotion, with risk information absent or presented only at the end.
How media format and placement contribute
The letters are about the ad as the viewer experienced it. That makes media decisions part of the analysis even when nobody on the media team wrote a word of copy.
- Unit size. A product claim squeezed into a small banner where ISI is unreadable.
- Video length and skip behavior. A short or skippable placement where the major statement comes after most viewers have left.
- Muted autoplay. A major statement carried only in audio, in an environment where most people watch without sound.
- Social formats. Truncated captions that hide risk behind a "see more" while the claim sits above the fold.
- Adjacency and sequencing. A help-seeking piece and a branded piece placed so that together they read as a product claim. See the three FDA ad types.
- Landing pages. A compliant banner that clicks through to a page making claims without nearby risk information.
Format specifics are covered in fair balance in digital pharma ads.
How to read an OPDP letter as a media professional
A simple routine works. Go to FDA's Untitled Letters page or search the warning letter database for the relevant center, open a recent letter, and work through it with these questions:
- What was the material, and where did it appear (TV, social, website, sponsored content, exhibit)?
- Which claims did FDA cite, and was the problem the claim itself or its presentation?
- How did FDA describe the risk presentation: placement, size, timing, audio, visuals?
- Would any of our current placements produce the same experience, even with approved copy?
- Does our format matrix have a rule that would have prevented this?
I would do this as a monthly 30-minute session with planners, ad ops, and social leads, one letter at a time. The point is not to second-guess regulatory colleagues. It is to recognize the patterns early so your submissions to MLR raise them before a reviewer has to. The MLR review for programmatic media article shows how to package that context.
What to change in your own process
The letters tend to point to the same fixes. Keep a format matrix that ties each placement to an approved risk treatment. Re-review legacy creative on a schedule rather than letting it run indefinitely. Treat paid influencer and partner content as advertising from the start. And when AI tools help draft copy or variants, keep a human reviewer accountable for net impression, as discussed in human review for AI-assisted healthcare marketing. For the broader set of DTC pressures, see the biggest challenges in US DTC pharma advertising, and for the whole map of regulators, the pharma marketing compliance guide.
Practical takeaway
Pull three recent OPDP letters from FDA's site this week. For each, write one sentence on what the viewer experienced and one sentence on which placement in your current plan could create a similar experience. Bring the list to your next MLR pre-submission meeting.
Frequently asked questions
What is the difference between an OPDP untitled letter and a warning letter?
Both tell a company that FDA believes a promotional piece is false or misleading. An untitled letter is used for violations FDA views as less serious and generally asks the company to stop using the materials. A warning letter signals more significant violations and usually asks for corrective action as well, and FDA indicates it may take further enforcement if the issues are not addressed.
Where can I read OPDP letters?
FDA posts warning letters in its warning letter database and posts OPDP untitled letters on a separate Untitled Letters page under its drug enforcement section. Letters may be redacted, and posting can lag the date the letter was sent.
Do OPDP letters name the agency or media vendor?
Letters are addressed to the company responsible for the product. They describe the material and where it appeared, but the regulatory responsibility sits with the manufacturer, even if an agency built or placed the ad.
Has OPDP enforcement increased recently?
Yes, by public accounts. FDA announced a large wave of DTC enforcement letters in September 2025 after several years of very few letters, and further letters followed into 2026. Check FDA's pages for the current pace.
Sources
- FDA, The Office of Prescription Drug Promotion (OPDP)
- FDA, Warning Letters and Notice of Violation Letters to Pharmaceutical Companies
- FDA, Untitled Letters
- FDA, About Warning and Close-Out Letters
- eCFR, 21 CFR 202.1 Prescription-drug advertisements
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.